全文获取类型
收费全文 | 4380篇 |
免费 | 227篇 |
国内免费 | 19篇 |
专业分类
耳鼻咽喉 | 23篇 |
儿科学 | 129篇 |
妇产科学 | 103篇 |
基础医学 | 536篇 |
口腔科学 | 90篇 |
临床医学 | 420篇 |
内科学 | 801篇 |
皮肤病学 | 93篇 |
神经病学 | 423篇 |
特种医学 | 105篇 |
外科学 | 498篇 |
综合类 | 19篇 |
一般理论 | 4篇 |
预防医学 | 500篇 |
眼科学 | 125篇 |
药学 | 275篇 |
中国医学 | 4篇 |
肿瘤学 | 478篇 |
出版年
2024年 | 3篇 |
2023年 | 45篇 |
2022年 | 95篇 |
2021年 | 176篇 |
2020年 | 120篇 |
2019年 | 147篇 |
2018年 | 158篇 |
2017年 | 115篇 |
2016年 | 130篇 |
2015年 | 132篇 |
2014年 | 177篇 |
2013年 | 229篇 |
2012年 | 357篇 |
2011年 | 344篇 |
2010年 | 217篇 |
2009年 | 204篇 |
2008年 | 259篇 |
2007年 | 304篇 |
2006年 | 284篇 |
2005年 | 243篇 |
2004年 | 210篇 |
2003年 | 221篇 |
2002年 | 154篇 |
2001年 | 23篇 |
2000年 | 19篇 |
1999年 | 17篇 |
1998年 | 43篇 |
1997年 | 30篇 |
1996年 | 19篇 |
1995年 | 19篇 |
1994年 | 18篇 |
1993年 | 17篇 |
1992年 | 5篇 |
1991年 | 9篇 |
1990年 | 6篇 |
1989年 | 10篇 |
1988年 | 5篇 |
1987年 | 7篇 |
1986年 | 4篇 |
1985年 | 2篇 |
1984年 | 4篇 |
1983年 | 5篇 |
1982年 | 14篇 |
1981年 | 5篇 |
1980年 | 3篇 |
1978年 | 3篇 |
1976年 | 2篇 |
1974年 | 3篇 |
1973年 | 2篇 |
1962年 | 1篇 |
排序方式: 共有4626条查询结果,搜索用时 15 毫秒
81.
Antiatherogenic effect of Pistacia lentiscus via GSH restoration and downregulation of CD36 mRNA expression 总被引:3,自引:0,他引:3
Dedoussis GV Kaliora AC Psarras S Chiou A Mylona A Papadopoulos NG Andrikopoulos NK 《Atherosclerosis》2004,174(2):293-303
Pistacia lentiscus var. Chia (Anacardiaceae) grows almost exclusively on Chios Island, Greece, and gives a resinous exudate resin used for culinary purposes by Mediterranean people. We investigated the molecular mechanisms through which total polar extract of the resin inhibits oxidized low-density lipoprotein (oxLDL) cytotoxic effect on peripheral blood mononuclear cell (PBMC). Cells exposed to oxLDL underwent apoptosis and necrosis, dependent on the duration of exposure. When culturing cells with oxLDL and the polar extract concurrently, we observed inhibition of both the phenomena. Because under oxidative stress the pro-oxidant systems outbalance the antioxidant, potentially producing oxidative damage and ultimately leading to cell death, we measured the levels of intracellular antioxidant glutathione (GSH). Additionally, we measured CD36 expression, a class B scavenger receptor, on CD14-positive cells, as CD36 has been identified as the oxLDL receptor in macrophages and may play a pivotal role in atherosclerotic foam cell formation. oxLDL decreased GSH levels and upregulated CD36 expression. P. lentiscus extract restored GSH levels and downregulated CD36 expression, even at the mRNA level. In order to find out the biologically drastic constituents of the resin's polar extract, fractions derived from RP-HPLC analysis were examined for their antioxidant effect on oxidatively stressed PBMC. The triterpenoid fraction revealed remarkable increase in intracellular GSH. We suggest GSH restoration and downregulation of CD36 mRNA expression as the pathways via which P. lentiscus triterpenes exert antioxidant/antiatherogenic effect. Additionally, our results provide strong evidence of the resin's antiatherogenic effect; therefore it is credited with beneficial health aspects. 相似文献
82.
83.
Antonio Pérez-Martínez Cristina Ferreras Antonia Pascual Marta Gonzalez-Vicent Laura Alonso Isabel Badell José María Fernández Navarro Alexandra Regueiro Mercedes Plaza Jose María Pérez Hurtado Ana Benito Cristina Beléndez José Miguel Couselo José Luis Fuster Mariana Díaz-Almirón David Bueno Yasmina Mozo Julia Marsal Alicia Gómez López Luisa Sisinni Cristina Díaz de Heredia Miguel Ángel Díaz 《American journal of hematology》2020,95(1):28-37
A total of 192 pediatric patients, median age 8.6 years, with high-risk hematological malignancies, underwent haploidentical stem cell transplantation (haplo-HSCT) using post-transplantation cyclophosphamide (PT-Cy), or ex vivo T cell-depleted (TCD) graft platforms, from January 1999 to December 2016 in 10 centers in Spain. Some 41 patients received an unmanipulated graft followed by PT-Cy for graft-vs-host disease (GvHD) prophylaxis. A total of 151 patients were transplanted with CD3-depleted peripheral blood stem cells (PBSCs) by either CD34+ selection, CD3+CD19+ depletion, TCRαβ+CD19+ depletion or CD45RA+ depletion, added to CD34+ selection for GvHD prophylaxis. The PBSCs were the only source in patients following ex vivo TCD haplo-HSCT; bone marrow was the source in 9 of 41 patients following PT-CY haplo-HSCT. Engraftment was achieved in 91.3% of cases. A donor younger than 30 years, and the development of chronic GvHD were positive factors influencing survival, whereas positive minimal residual disease (MRD) before transplant and lymphoid disease were negative factors. The probability of relapse increased with lymphoid malignancies, a donor killer-cell immunoglobulin-like receptor (KIR) haplotype A and positive MRD pretransplant. No difference was found in overall survival, disease-free survival or relapse incidence between the two platforms. Relapse is still of concern in both platforms, and it should be the focus of future efforts. In conclusion, both platforms for haplo-HSCT were effective and could be utilized depending on the comfort level of the center. 相似文献
84.
85.
86.
Shengfang Su Gary Kay Thomas Hochadel Jonathan Rojo J. Christopher Stein Ramesh Boinpally Antonia Periclou 《CTS Clinical and Translational Science》2022,15(1):255
N‐methyl‐D‐aspartate ionotropic glutamatergic receptor (NMDAR) modulators, including rapastinel and ketamine, elicit rapid and sustained antidepressant responses in patients with treatment‐resistant major depressive disorder. This phase I, randomized, multicenter, placebo‐controlled, five‐period, crossover, single‐dose study evaluated simulated driving performance of healthy participants (N = 107) after single doses of rapastinel slow intravenous (i.v.) bolus 900 and 1800 mg, alprazolam oral 0.75 mg (positive control), ketamine i.v. infusion 0.5 mg/kg (clinical comparator), and placebo ~ 45 min before driving. The primary end point was SD of lateral position (SDLP) during the 60‐min 100‐km simulated driving scenario. Additional measures of driving performance, sleepiness, and cognition were also evaluated. To assess effects over time, mean SDLP was calculated for each 10‐min interval of driving. Sensitivity of the assays was confirmed with alprazolam (all placebo comparisons p < 0.02). Rapastinel 900 and 1800 mg did not significantly affect simulated driving performance compared to placebo (both p > 0.5). Both rapastinel doses resulted in significantly less impaired driving compared to alprazolam or ketamine (all p < 0.002); ketamine significantly impaired driving compared to placebo (p = 0.0001). Results for the additional measures were similar to the primary end point. No new safety signals were observed for any study interventions. This first study of rapastinel effects on simulated driving found that rapastinel 900 and 1800 mg did not impair driving performance, but ketamine 0.5 mg/kg resulted in significantly impaired driving performance. Ketamine’s effects on driving were maintained for at least 105 min, indicating that clinicians should be vigilant to prevent or postpone driving in patients after ketamine treatment. Study Highlights
- WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
- WHAT QUESTION DID THIS STUDY ADDRESS?
- WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
- HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?
87.
Laura Homzova Joachim Photiadis Nicodme Sinzobahamvya Stanislav Ovroutski Mi-Young Cho Antonia Schulz 《Interactive Cardiovascular and Thoracic Surgery》2021,32(4):593
OBJECTIVESOur goal was to evaluate the impact of the adult congenital heart disease anatomical and physiological (ACHD AP) classification system on the surgical management of Ebstein anomaly (EA) in adult patients.METHODSFrom February 2000 through August 2017, data of patients aged at least 16 years, who underwent primary EA surgery, were retrospectively evaluated. The cohort was divided in 2 groups according to their ACHD AP classification: the moderate EA group (IIB, IIC) and the severe EA group (IID). Survival, freedom from reoperation and freedom from occurrence of major adverse advents were estimated.Open in a separate windowRESULTSThere were 33 patients (21 women, 12 men). Eighteen belonged to the moderate group, 15 to the severe group. There were 12 female patients (80%) in the severe group. Patients in the moderate group were younger than those in the severe group (P = 0.02): 32 ± 12 vs 44 ± 15 years old. Thirty tricuspid valve repairs and 3 replacements were performed. Repair was mainly performed in the moderate group (P = 0.02). Overall survival was 90.1 ± 5.4% at 9 months after the operation and did not change in the later follow-up period. It was 100% for patients in the moderate group and 80.0 ± 10.3% in the severe group (P = 0.07), and 75.0 ± 12.5% for female patients of in the severe group compared to 100% for the remaining patients (P = 0.025). Survival free from major adverse events, including reoperation, at 10 years was 60.0 ± 12.6% in the moderate and 38.1% ± 12.9% in the severe group (P = 0.03). No patient in the moderate group evolved to be in the severe group at late follow-up.CONCLUSIONAdult EA patients should undergo surgery earlier when they are still in the moderate ACHD AP classification. 相似文献
88.
Jos Antonio Lpez-Guerrero Maria Antonia Ortiz Eduardo Pez Carmelo Bernabu Juan Pedro Lpez-Bote 《Arthritis \u0026amp; Rheumatology》1994,37(10):1462-1467
Objective. To analyze the effects of recombinant viruses for 2 heat-shock proteins in the treatment of adjuvant arthritis. Methods. Virus vaccinia recombinant for mycobacterial heat-shock protein 65 (hsp65-VV) and human hsp60 (hsp60-VV) were administered to rats during different stages of adjuvant arthritis. Arthritis score and immunity to the recombinant virus were analyzed. Results. When delivered at the pre-arthritis stage, both constructs ameliorated arthritis; greater protection was observed with hsp60-VV. A specific T cell response to the recombinant proteins was detected. Furthermore, hsp60-VV displayed a clear therapeutic effect on established arthritis. Conclusion. Our results suggest novel avenues of therapeutic intervention in autoimmune arthritis associated with immunity to hsp60. 相似文献
89.
Ana Belen Granado-Serrano Meritxell Martín-Garí Virginia Snchez Marissa Riart Solans Antonia Lafarga Giribets Rebeca Berdún Ester Vilapriny Manuel Portero-Otín Jos C. E. Serrano 《Nutrients》2022,14(3)
This study aimed to determine how the microbiota profile might be predisposed to a better response in blood lipid profiles due to dietary fibre supplementation. A three-arm intervention study that included three different fibre types (mainly insoluble, soluble, and antioxidant fibre) supplemented (19.2 g/day) during 2 months in individuals with hypercholesterolemia was developed. Changes in faecal microbiota and blood lipid profile after fibre supplementation were determined. In all volunteers, regardless of fibre type, an increase in the abundance of Bifidobacterium was observed, and similarly, an inverse relationship between faecal propionic acid and blood LDL-cholesterol, LDL particle size, and LDL/HDL particle ratio (p-values 0.0067, 0.0002, and 0.0067, respectively) was observed. However, not all volunteers presented an improvement in lipid profile. The non-responders to fibre treatment showed a decrease in microbiota diversity (Shannon and Simpson diversity index p-values of 0.0110 and 0.0255, respectively) after the intervention; where the reduction in short-chain fatty acids (SCFAs) producing bacterial genera such as Clostridium XIVa and Ruminococcus after dietary fibre treatment was the main difference. It was concluded that the non-responsiveness to dietary fibre treatment might be mediated by the lack of ability to maintain a stable SCFA producing bacteria diversity and composition after extra fibre intake. 相似文献
90.
Kulisevsky Jaime Bejr-Kasem Helena Martinez-Horta Saul Horta-Barba Andrea Pascual-Sedano Berta Campolongo Antonia Marín-Lahoz Juan Aracil-Bolaños Ignacio Pérez-Pérez Jesús Izquierdo-Barrionuevo Cristina de Fàbregues Oriol Puente Victor Crespo-Cuevas Ane Calopa Matilde Pagonabarraga Javier 《Journal of neurology》2020,267(11):3400-3410
Journal of Neurology - Chronic levodopa treatment in Parkinson’s disease (PD) may promote undesirable motor and non-motor fluctuations. Compared to chronic oral levodopa treatment, continuous... 相似文献